Abstract
Patients in the original Familial Atherosclerosis Treatment Study (FATS) cohort were subgrouped into those with triglyceride levels < or = 120 mg/dL (n = 26) and those with triglyceride levels > or = 190 mg/dL (n = 40). Their therapeutic responses to niacin plus colestipol, lovastatin plus colestipol, colestipol alone, or placebo were determined. Therapeutic response was also determined in the same 2 triglyceride subgroups (n = 12 and n = 27, respectively) of patients selected for low levels of high-density lipoprotein (HDL) cholesterol and coronary artery disease. These triglyceride criteria were chosen to identify patient subgroups with high likelihood of "pattern A" (normal-size low-density lipoprotein [LDL] particles and triglyceride < or = 120 mg/dL) or "pattern B" (small dense LDL and triglyceride > or = 190 mg/dL). Our findings in these small patient subgroups are consistent with the emerging understanding that coronary artery disease patients presenting with high triglyceride levels have lower HDL-C, smaller less buoyant LDL-C, and greater very low-density lipoprotein (VLDL) cholesterol and VLDL apolipoprotein B, and are more responsive to therapy as assessed by an increase in HDL-C and reduction in triglycerides, VLDL-...Continue Reading
References
Jan 1, 1992·Circulation·V ManninenM H Frick
Nov 8, 1990·The New England Journal of Medicine·G BrownH T Dodge
Dec 1, 1993·Circulation·N R PhillipsR J Havel
Sep 18, 1996·JAMA : the Journal of the American Medical Association·M J StampferC H Hennekens
Nov 1, 1996·Circulation·B D MillerR M Krauss
Jan 7, 1997·Circulation·S M Grundy
Citations
Jan 1, 2006·Women's Health·Bina AhmedGeorge Sopko
Feb 24, 2007·Vascular Health and Risk Management·James M BackesPatricia A Howard
Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·H R Superko
Apr 11, 2003·Current Treatment Options in Cardiovascular Medicine·H. Robert Superko, Nicolas A. Chronos
Apr 18, 2001·Journal of Clinical Pharmacology·T D Dayspring
Oct 28, 2008·Current Cardiology Reports·Peter P Toth
Oct 30, 2013·International Journal of Clinical Practice·A BhargavaK V S N Yarlagadda
Oct 3, 2012·Acta Physiologica·J WeiT-S Lee
Sep 14, 1999·The American Journal of Medicine·C East
Sep 30, 2008·International Journal of Clinical Practice·A S Wierzbicki
Jun 20, 2008·International Journal of Clinical Practice·A S Wierzbicki
Mar 27, 2010·Journal of the American College of Cardiology·Pradeep NatarajanChristopher P Cannon
Jan 15, 2000·Journal of the American College of Cardiology·C J VaughanC T Basson
Feb 9, 2002·Preventive Cardiology·K A BybeeT M Bateman
Jul 2, 2002·Preventive Cardiology·Monte Malach, Pascal James Imperato
Jan 27, 2005·The Annals of Pharmacotherapy·James M Backes, Cheryl A Gibson
Sep 7, 2011·Therapeutic Advances in Cardiovascular Disease·Willibald HochholzerRobert P Giugliano
Feb 26, 2009·Angiology·Thomas F Whayne
May 25, 2002·Heart Disease·Harry B Burke
Nov 16, 2011·Clinical Medicine Insights. Cardiology·Helen Vosper
Apr 23, 2008·Journal of Cardiovascular Pharmacology·Madiha Abdel-MaksoudJohn E Hokanson
Mar 30, 1999·Journal of Computer Assisted Tomography·T Kristensen, E W Olcott
Apr 7, 1999·Current Opinion in Cardiology·L J SemanE J Schaefer